QuidelOrtho Corporation (QDEL)
| Bid | 33 |
| Market Cap | 2.39B |
| Revenue (ttm) | 2.79B |
| Net Income (ttm) | -2.03B |
| EPS (ttm) | -30.54 |
| PE Ratio (ttm) | -1.16 |
| Forward PE | 18.57 |
| Analyst | Buy |
| Ask | 37.3 |
| Volume | 658,103 |
| Avg. Volume (20D) | 872,108 |
| Open | 35.21 |
| Previous Close | 36.51 |
| Day's Range | 35.15 - 37.24 |
| 52-Week Range | 29.74 - 49.45 |
| Beta | 0.10 |
About QDEL
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical managem...
Analyst Forecast
According to 5 analyst ratings, the average rating for QDEL stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 41.20% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial ResultsSAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...
2 months ago · businesswire.com
QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs ...